Upstream Bio (NASDAQ:UPB) Trading Down 7.3% – What’s Next?

Shares of Upstream Bio, Inc. (NASDAQ:UPB) traded down 7.3% during trading on Monday . The company traded as low as $9.91 and last traded at $9.98. 18,696 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 238,480 shares. The stock had previously closed at $10.77.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on UPB shares. TD Cowen began coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. assumed coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $38.00 target price on the stock. Piper Sandler began coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $75.00 target price for the company. Finally, William Blair began coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They issued an “outperform” rating for the company.

Upstream Bio Stock Performance

The stock’s fifty day simple moving average is $16.57.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($6.38). The business had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.83 million. As a group, equities analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Hedge Funds Weigh In On Upstream Bio

A hedge fund recently bought a new stake in Upstream Bio stock. Moody Aldrich Partners LLC purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 74,773 shares of the company’s stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned approximately 0.14% of Upstream Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.